In August, President Biden signed the Inflation Reduction Act into law, which will undoubtedly have major impacts on the Medicare market. As provisions start to take effect, drug manufacturers should take the time now to understand key provisions such as Part B/D inflation rebate penalties, $35 insulin copay caps, Part D benefit redesign, and government negotiation of drug prices. In this article for PM360, we lay out key items to watch and preparation strategies for the next three years and beyond.

Read the full article here.